CoChat

Inhibition of Proteasome Activity Upregulates IL-6 Expression in RPE Cells through the Activation of P38 MAPKs

Open access
Qin, Tingyu, Gao, Shasha · 2018 · Journal of Ophthalmology

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Purpose. As far as we know, during the development of age-related macular degeneration (AMD), the activity of proteasome in retinal pigment epithelium cells (RPE) gradually decreases. And a lot of research has shown that age-related macular degeneration is closely related to inflammation and autoimmune. Moreover, there are many cytokines (CKs) involved in the course of inflammation. In this study, we are going to investigate how the decrease of proteasome activity affects the production of interleukin-6 (IL-6) in human retinal pigment epithelium cells (ARPE-19).Methods. Cultured ARPE-19 was treated with or without MG132, a proteasome inhibitor, and the levels of IL-6 mRNA (messenger ribonucleic acid) in RPE at 1 h, 4 h, 8 h, and IL-6 protein in the culture medium at 2 h, 4 h, 6 h, 8 h, 10 h, and 12 h were measured by real-time polymerase chain reaction (real-time PCR) and enzyme-linked immunosorbent assay (ELISA). The protein levels of MCP-1 (monocyte chemoattractant protein-1) in the culture medium at 2 h, 4 h, 6 h, 8 h, 10 h, and 12 h were also measured by ELISA. Then we tested which of cell signal pathways regulating the production of IL-6 were activated when we added MG132 into the medium by Western blot and electrophoretic mobility shift assays (EMSA). After that, we put the inhibitors of these activated cell signal pathways into the medium individually to see which inhibitor can counteract the effect of upregulating the levels of IL-6 in the culture medium of RPE.Results. MG132 decreased the secretion of MCP-1 in the culture medium of RPE, but it increased the expression of IL-6 mRNA in RPE and IL-6 protein level in the culture medium of RPE. MG132 treatment was also found to enhance the level of phosphorylated p38 mitogen-activated protein kinases (MAPKs) and c-Jun N-terminal Kinase (JNK) by Western blotting. More importantly, the effect of MG132 on upregulating the levels of IL-6 was inhibited by SB203580, an inhibitor of P38 MAP kinases. But the JNK inhibitor, SP600125, cannot prevent the effect of upregulating the levels of IL-6 by MG132 in the RPE culture medium.Conclusions. We concluded that the proteasome inhibitor, MG132, upregulates IL-6 production in RPE cells through the activation of P38 MAPKs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2018/5392432

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Proteasome inhibition upregulated IL-6 mRNA production in RPE. ARPE-19 cells were cultured in the presence of MG132 for 1, 4, and 8 h. Levels of mRNA for IL-6 were assessed by real-time RT-PCR analysis. GAPDH mRNA was used as a control to normalize the total mRNA levels. The results are the mean ± SD of two independent experiments.
Figure 1 Proteasome inhibition upregulated IL-6 mRNA production in RPE. ARPE-19 cells were cultured in the presence of MG132 for 1, 4, and 8 h. Levels of mRNA for IL-6 were assessed by real-time RT-PCR analysis. GAPDH mRNA was used as a control to normalize the total mRNA levels. The results are the mean ± SD of two independent experiments.CC BY · PubMed Central
Figure 2 Protease inhibitor MG132 upregulated the protein level of IL-6 in the medium of RPE in MG132 group compared with that in the control group, but it reduced the secretion of MCP-1. (a) Levels of IL-6 in the medium were detected by ELISA following incubation of ARPE-19 cells in the presence or absence of MG132 (10 μM) for 2, 4, 6, 8, 10, or 12 h. (b) Levels of IL-6 in the medium were detected by ELISA during 0 h–6 h or 6 h–12 h in the presence or absence of MG132 (10 μM). (c) Levels of MCP-1 in the medium were detected by ELISA following incubation of ARPE-19 cells in the presence or absence of MG132 (10 μM) for 2, 4, 6, 8, 10, or 12 h. (d) Levels of MCP-1 in the medium were detected by ELISA during 0 h–6 h or 6 h–12 h in the presence or absence of MG132 (10 μM). The results are the mean ± SD ∗p < 0.05 and ∗∗p < 0.01 as compared with the control.
Figure 2 Protease inhibitor MG132 upregulated the protein level of IL-6 in the medium of RPE in MG132 group compared with that in the control group, but it reduced the secretion of MCP-1. (a) Levels of IL-6 in the medium were detected by ELISA following incubation of ARPE-19 cells in the presence or absence of MG132 (10 μM) for 2, 4, 6, 8, 10, or 12 h. (b) Levels of IL-6 in the medium were detected by ELISA during 0 h–6 h or 6 h–12 h in the presence or absence of MG132 (10 μM). (c) Levels of MCP-1 in the medium were detected by ELISA following incubation of ARPE-19 cells in the presence or absence of MG132 (10 μM) for 2, 4, 6, 8, 10, or 12 h. (d) Levels of MCP-1 in the medium were detected by ELISA during 0 h–6 h or 6 h–12 h in the presence or absence of MG132 (10 μM). The results are the mean ± SD ∗p < 0.05 and ∗∗p < 0.01 as compared with the control.CC BY · PubMed Central
Figure 3 Proteasome inhibitor (MG132, 10 μM) can activate p38 MAPK and JNK in RPE. (a) ARPE-19 cells were cultured in the absence or presence of the proteasome inhibitor MG132 (10 μM) for 1, 2, 4, and 8 h. Levels of endogenous phospho-p38 MAPK, total p38 MAPK, and actin were detected by Western blot using polyclonal (to phosphorylated and total p38 MAPK) and monoclonal antibodies (to actin). ∗Is the only one phosphorylated site of P38 MAPK. (b) ARPE-19 cells were cultured in the absence or presence of the proteasome inhibitor MG132 (10 μM) for 1, 2, 4, and 8 h. Levels of endogenous phospho-JNK, total JNK, and actin were detected by Western blot using polyclonal (to phosphorylated and total JNK) and monoclonal antibodies (to actin).
Figure 3 Proteasome inhibitor (MG132, 10 μM) can activate p38 MAPK and JNK in RPE. (a) ARPE-19 cells were cultured in the absence or presence of the proteasome inhibitor MG132 (10 μM) for 1, 2, 4, and 8 h. Levels of endogenous phospho-p38 MAPK, total p38 MAPK, and actin were detected by Western blot using polyclonal (to phosphorylated and total p38 MAPK) and monoclonal antibodies (to actin). ∗Is the only one phosphorylated site of P38 MAPK. (b) ARPE-19 cells were cultured in the absence or presence of the proteasome inhibitor MG132 (10 μM) for 1, 2, 4, and 8 h. Levels of endogenous phospho-JNK, total JNK, and actin were detected by Western blot using polyclonal (to phosphorylated and total JNK) and monoclonal antibodies (to actin).CC BY · PubMed Central
Figure 4 Proteasome inhibition can activate AP-1.
Figure 4 Proteasome inhibition can activate AP-1.CC BY · PubMed Central
Figure 5 JNK inhibitor (SP600125) can reduce the activation of c-Jun in a dose-dependent way.
Figure 5 JNK inhibitor (SP600125) can reduce the activation of c-Jun in a dose-dependent way.CC BY · PubMed Central
Figure 6 Inhibition of JNK cannot block proteasome inhibition-induced upregulation of IL-6. (a) ARPE-19 cells were cultured in the presence or absence of MG132 (10 μM), Sp600125 (40 μM), or MG132 plus Sp600125 for 2, 4, 6, 8, 10, and 12 h. Levels of IL-6 in the media were determined by ELISA. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.01 as compared with the control or Sp600125 alone; ##p < 0.05 as compared with the control or Sp600125 alone. (b) Levels of IL-6 in the medium were detected by ELISA at 0 h–6 h and 6 h–12 h in the presence or absence of MG132 (10 μM), SP600125 (40 μM), or MG132 plus SP600125. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.05 as compared with the control or Sp600125 alone. (c) To study whether JNK inhibition can block the activation of AP-1 induced by proteasome inhibition, the RPE cells were cultured in the presence or absence of MG132 (10 μM), SP600125 (40 μM), or MG132 plus SP600125 for 4 h; nuclear extracts were prepared; and electrophoretic mobility gel shift assays were performed for AP-1 binding. Coomassie staining gel was the internal standard.
Figure 6 Inhibition of JNK cannot block proteasome inhibition-induced upregulation of IL-6. (a) ARPE-19 cells were cultured in the presence or absence of MG132 (10 μM), Sp600125 (40 μM), or MG132 plus Sp600125 for 2, 4, 6, 8, 10, and 12 h. Levels of IL-6 in the media were determined by ELISA. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.01 as compared with the control or Sp600125 alone; ##p < 0.05 as compared with the control or Sp600125 alone. (b) Levels of IL-6 in the medium were detected by ELISA at 0 h–6 h and 6 h–12 h in the presence or absence of MG132 (10 μM), SP600125 (40 μM), or MG132 plus SP600125. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.05 as compared with the control or Sp600125 alone. (c) To study whether JNK inhibition can block the activation of AP-1 induced by proteasome inhibition, the RPE cells were cultured in the presence or absence of MG132 (10 μM), SP600125 (40 μM), or MG132 plus SP600125 for 4 h; nuclear extracts were prepared; and electrophoretic mobility gel shift assays were performed for AP-1 binding. Coomassie staining gel was the internal standard.CC BY · PubMed Central
Figure 7 Inhibition of p38 MAPK blocks proteasome inhibition-induced upregulation of IL-6. (a) ARPE-19 cells were cultured in the presence or absence of MG132 (10 μM), SB203580 (10 μM), or MG132 plus SB203580 for 2, 4, 6, 8, 10, and 12 h. Levels of IL-6 in the media were determined by ELISA. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.05 as compared with the control or SB203580 alone. (b) Levels of IL-6 in the medium were detected by ELISA at 0 h–6 h and 6 h–12 h in the presence or absence of MG132 (10 μM), SB203580 (10 μM), or MG132 plus SB203580. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.05 as compared with the control or SB203580 alone.
Figure 7 Inhibition of p38 MAPK blocks proteasome inhibition-induced upregulation of IL-6. (a) ARPE-19 cells were cultured in the presence or absence of MG132 (10 μM), SB203580 (10 μM), or MG132 plus SB203580 for 2, 4, 6, 8, 10, and 12 h. Levels of IL-6 in the media were determined by ELISA. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.05 as compared with the control or SB203580 alone. (b) Levels of IL-6 in the medium were detected by ELISA at 0 h–6 h and 6 h–12 h in the presence or absence of MG132 (10 μM), SB203580 (10 μM), or MG132 plus SB203580. The results are the mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 as compared with the control; #p < 0.05 as compared with the control or SB203580 alone.CC BY · PubMed Central
Figure 8 The activation of AP-1 induced by proteasome inhibition is not blocked by the inactivation of P38 MAPK.
Figure 8 The activation of AP-1 induced by proteasome inhibition is not blocked by the inactivation of P38 MAPK.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 3

  1. 2003, Current Opinion in Investigational Drugs, 4, 1333
  2. 2010, Molecular Vision Other Titles, 16, 1864
  3. 2007, Bulletin of the NYU Hospital for Joint Diseases, 65, S16

Cited by

See all 14

Metadata

Authors
Qin, T., & Gao, S.
Affiliations
First Affiliated Hospital of Zhengzhou University (CN)
Corresponding author
Gao, Shasha
Venue
Journal of Ophthalmology
Publisher
Wiley
Published
2018-07-12
Volume
2018
Pages
1-8
ISSN
  • 2090-004X (ISSN-L)
  • 2090-0058
OpenAlex
W2864177024
Cited by
13
References
55
Citations by year
2025: 1 · 2024: 2 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 2
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • Journal of Ophthalmology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Medical Science and Technology Project of Health and Family Planning Commission (201403055, 201503056, 1455, 19A320059, 19A320078)
  • Key Research and Development and Promotion Project (201403055, 201503056, 1455, 19A320059, 19A320078)
  • Key Scientific Research Projects (201403055, 201503056, 1455, 19A320059, 19A320078)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
proteasome inhibition, interleukin-6, retinal pigment epithelium, age-related macular degeneration, p38 MAPK, JNK, MCP-1, ARPE-19 cells, MG132, inflammation, cytokine expression, signaling pathways, SB203580, c-Jun N-terminal kinase, MAPKAPK

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of Proteasome Activity Upregulates IL-6 Expression in RPE Cells through the Activation of P38 MAPKs. https://app.cochat.ai/papers/10.1155/2018/5392432
The paper
Qin, T., & Gao, S. (2018). Inhibition of Proteasome Activity Upregulates IL-6 Expression in RPE Cells through the Activation of P38 MAPKs. Journal of Ophthalmology. https://doi.org/10.1155/2018/5392432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.